Aromatase inhibitors: a safety comparison (Q36762444)

16 August 2017

1 reference

title

Aromatase inhibitors: a safety comparison (English)

1 reference

16 August 2017

1

Walter Jonat

0 references

Felix Hilpert

series ordinal

2

object named as

Felix Hilpert

1 reference

16 August 2017

Manfred Kaufmann

3

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 March 2007

1 reference

Expert Opinion on Drug Safety

16 August 2017

published in

1 reference

16 August 2017

volume

6

1 reference

16 August 2017

issue

2

1 reference

16 August 2017

page(s)

165-174

1 reference

Global cancer statistics, 2002

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.165

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.165

Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.165

Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.165

An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.165

Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.165

American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.165

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.165

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.165

Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.165

Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.165

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.165

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.165

Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.165

Effect of letrozole on the lipid profile in postmenopausal women with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.165

The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.165

The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane o

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.165

The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: preliminary results of the TEAM Greek sub-study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.165

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.165

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.165

Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.165

Discussions regarding reproductive health for young women with breast cancer undergoing chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.165

Sequencing of tamoxifen and radiotherapy after breast-conserving surgery in early-stage breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.165

The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.165

Economic burden associated with breast cancer recurrence: findings from a retrospective analysis of health system data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.165

Should aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.165

Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.165

Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.165

21 January 2018

Identifiers

DOI

10.1517/14740338.6.2.165

1 reference

16 August 2017

1 reference